Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Steurer

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 23, 2013
Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosisArmin Finkenstedt, Claudia Auer, Bernhard Glodny, et al.
Haematologica|April 16, 2017
Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopeniaDouglas B Cines, Jeffrey Wasser, Francesco Rodeghiero, et al.
European Journal of Haematology|April 1, 2018
Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemiaVeronika Buxhofer-Ausch, Michael Steurer, Siegfried Sormann, et al.
Annals of Hematology|September 12, 2014
Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damagePeter Valent, Jörg Berger, Sabine Cerny-Reiterer, et al.
European Journal of Haematology|August 26, 2016
A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practiceMichael Steurer, Philippe Quittet, Helen A Papadaki, et al.
Leukemia Research|April 9, 2015
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational studyGiovanni Tortorella, Andrea Piccin, Alessia Tieghi, et al.
Blood Transfusion = Trasfusione Del Sangue|August 3, 2016
Platelet gel: a new therapeutic tool with great potentialAndrea Piccin, Angela M Di Pierro, Lucia Canzian, et al.
Annals of Hematology|February 26, 2011
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patientsMichael Fiegl, Florian Falkner, Michael Steurer, et al.
British Journal of Haematology|January 30, 2020
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short reportUdvardy Miklos, Vladimir Strugov, Catharina Lewerin, et al.
Acta Haematologica|June 13, 2015
Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and SeverityAnn Janssens, Michael Tarantino, Robert J Bird, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 23, 2013
Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosisArmin Finkenstedt, Claudia Auer, Bernhard Glodny, et al.
Haematologica|April 16, 2017
Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopeniaDouglas B Cines, Jeffrey Wasser, Francesco Rodeghiero, et al.
European Journal of Haematology|April 1, 2018
Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemiaVeronika Buxhofer-Ausch, Michael Steurer, Siegfried Sormann, et al.
Annals of Hematology|September 12, 2014
Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damagePeter Valent, Jörg Berger, Sabine Cerny-Reiterer, et al.
European Journal of Haematology|August 26, 2016
A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practiceMichael Steurer, Philippe Quittet, Helen A Papadaki, et al.
Leukemia Research|April 9, 2015
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational studyGiovanni Tortorella, Andrea Piccin, Alessia Tieghi, et al.
Blood Transfusion = Trasfusione Del Sangue|August 3, 2016
Platelet gel: a new therapeutic tool with great potentialAndrea Piccin, Angela M Di Pierro, Lucia Canzian, et al.
Annals of Hematology|February 26, 2011
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patientsMichael Fiegl, Florian Falkner, Michael Steurer, et al.
British Journal of Haematology|January 30, 2020
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short reportUdvardy Miklos, Vladimir Strugov, Catharina Lewerin, et al.
Acta Haematologica|June 13, 2015
Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and SeverityAnn Janssens, Michael Tarantino, Robert J Bird, et al.
Pageof 8